How your com­pa­ny can fund the work at End­points News — and give your em­ploy­ees com­plete ac­cess to our con­tent

Last sum­mer we launched a prod­uct — En­ter­prise — that is es­sen­tial to the fu­ture of End­points News. Cor­po­rate cus­tomers can now di­rect­ly sup­port our fu­ture de­vel­op­ment through paid sub­scrip­tions, and get a list of ex­tra ben­e­fits and con­tent. If you’d like to sup­port the work, please con­sid­er do­ing so to­day. (We al­so have a prod­uct for in­di­vid­u­als called In­sid­er, which you can read about here.)

The news is this: We want to hit our sub­scrip­tion rev­enue goals now so we can ex­pand the team, bring­ing you even bet­ter re­port­ing soon­er rather than lat­er.  It’s just $1,000/year for your en­tire com­pa­ny no mat­ter the size — and you can see one of the ben­e­fits be­low. Every em­ploy­ee who sub­scribes to End­points News will be­gin to see this new spe­cial email head­er that demon­strates your com­pa­ny’s sup­port.

Spe­cial head­er em­ploy­ees would see with an En­ter­prise sub­scrip­tion


This isn’t a plea for do­na­tions. With a paid sub­scrip­tion, we’re pro­vid­ing you val­ue and new tools (more on that be­low) and in ex­change we’re charg­ing a price.

To do in­de­pen­dent jour­nal­ism root­ed in the style John and I have set out since we launched — 2 years, 3,700 ar­ti­cles and 500 dai­ly newslet­ters ago — here’s one ab­solute truth: Read­ers must di­rect­ly sup­port the busi­ness mod­el. And now your com­pa­ny can.

Give your em­ploy­ees full ac­cess to end­points news

Let’s say your com­pa­ny has 2,000 em­ploy­ees. Per­haps 500 of them vis­it our web­site and 50 of them are free email sub­scribers. For just $1,000/year, you can in­stant­ly up­grade all 50 to En­ter­prise — and then as long as your sub­scrip­tion is cur­rent, we’ll au­to­mat­i­cal­ly flag all new email sub­scribers from your cor­po­rate do­main and grant them full ac­cess to your firm’s En­ter­prise li­cense.

All of your em­ploy­ees who sub­scribe to End­points News will see the spe­cial head­er in their newslet­ter, re­mind­ing them of your com­pa­ny’s sup­port of in­de­pen­dent jour­nal­ism. We’ll send them all pre­mi­um End­points con­tent which is ex­clu­sive to paid sub­scribers on­ly. And there’s more. Your em­ploy­ees al­so get:

  • Print-to-PDF: The PDF but­ton above all our news ar­ti­cles will now work.
  • Cut-and-paste rights: Share our work legal­ly in full, with­out the URL, in­ter­nal­ly or with part­ners, in any dig­i­tal medi­um. A huge li­brary of news con­tent at their fin­ger­tips. With­out a sub­scrip­tion, just a fair-use, lim­it­ed amount is per­mis­si­ble.
  • Reprint rights: Go ahead and print our ma­te­r­i­al for busi­ness use, they’d have our full per­mis­sion.

And now:

    • Two Pre­mi­um Job List­ings: At End­points Ca­reers, we of­fer a way for cor­po­rate sub­scribers to get their open po­si­tions in front of our en­tire sub­scriber base. We’re of­fer­ing two free Pre­mi­um List­ings per year to each cor­po­rate cus­tomer. That is an $1,800 cost by it­self, which alone ex­ceeds the cost of a one year sub­scrip­tion.

Pay­wall ac­cess

Once you sub­scribe, here’s just a sam­ple of the con­tent every­one at your com­pa­ny will have ac­cess to:

Where the mon­ey is: Top 100 VCs in­vest­ing in US biotechs dur­ing 2017


What you need to know about this record-set­ting biotech IPO burst as 5 more crash the par­ty look­ing for $547M


The good, the bad and the ug­ly for the top 15 spenders in the glob­al drug R&D busi­ness: 2018


Where does the sci­ence come from? The top 20 NIH-fund­ed in­sti­tu­tions in 2017


What are the top 10 cor­po­rate VCs in bio­phar­ma to­day? And what do they want to fund — or steer clear of?


The top 20 rare dis­ease spe­cial­ists spot­light key biotech trends be­hind the boom

… and much more to come


Now is the time to sup­port the work

To the hun­dreds of amaz­ing com­pa­nies and in­di­vid­u­als who’ve al­ready signed up, thank you — what we do isn’t pos­si­ble with­out you.

If you’ve been think­ing about it but have put it off, we to­tal­ly get it. But we need your help this month if we’re to hit the lofty to­tals that’ll al­low us to hire a top-class team and build new prod­ucts while main­tain­ing our in­de­pen­dence.

Get End­points En­ter­prise

We’ve de­signed a re­al­ly easy form that takes a cou­ple min­utes to fill out, and re­quires a cred­it card pay­ment at the end. With­in 24 hours, usu­al­ly much soon­er, you’ll get an email with a full PDF li­cense. You can see the en­tire terms and con­di­tions here. All of your em­ploy­ees can start en­joy­ing the ben­e­fits of a sub­scrip­tion im­me­di­ate­ly.

Need help? Now many com­pa­nies have com­pli­cat­ed billing process­es and pro­to­cols. You can chat with our team dur­ing busi­ness hours via our up­grade page or Read­er Cen­ter should you re­quire spe­cial as­sis­tance. To sign in, you can use a tra­di­tion­al pass­word or click a se­cure “mag­ic link” that we send to your email on file with us. You can al­so send an email to help@end­pointsnews.com.

We re­quire a cred­it card pay­ment but in lim­it­ed cir­cum­stances can in­voice your com­pa­ny if there is no al­ter­na­tive.

To be­gin your com­pa­ny’s paid sub­scrip­tion, click on the but­ton be­low.

Get End­points En­ter­prise

Once again, this is a cru­cial month for this com­pa­ny. You can di­rect­ly sup­port our fu­ture de­vel­op­ment, so we can build on the track we’ve laid so far. We’ll have more posts over the month on our pro­grams but we need your sup­port to­day. Thanks for be­ing part of the End­points News com­mu­ni­ty.

Chas­ing Roche's ag­ing block­buster fran­chise, Am­gen/Al­ler­gan roll out Avastin, Her­ceptin knock­offs at dis­count

Let the long battle for biosimilars in the cancer space begin.

Amgen has launched its Avastin and Herceptin copycats — licensed from the predecessors of Allergan — almost two years after the FDA had stamped its approval on Mvasi (bevacizumab-awwb) and three months after the Kanjinti OK (trastuzumab-anns). While the biotech had been fielding biosimilars in Europe, this marks their first foray in the US — and the first oncology biosimilars in the country.

Seer adds ex-FDA chief Mark Mc­Clel­lan to the board; Her­cules Cap­i­tal makes it of­fi­cial for new CEO Scott Bluestein

→ On the same day it announced a $17.5 million Series C, life sciences and health data company Seer unveiled that it had lured former FDA commissioner and ex-CMS administrator Mark McClellan on to its board. “Mark’s deep understanding of the health care ecosystem and visionary insights on policy reform will be crucial in informing our thinking as we work to bring our liquid biopsy and life sciences products to market,” said Seer chief and founder Omid Farokhzad in a statement.

Norbert Bischofberger. Kronos

Backed by some of the biggest names in biotech, Nor­bert Bischof­berg­er gets his megaround for plat­form tech out of MIT

A little over a year ago when I reported on Norbert Bischofberger’s jump from the CSO job at giant Gilead to a tiny upstart called Kronos, I noted that with his connections in biotech finance, that $18 million launch round he was starting off with could just as easily have been $100 million or more.

With his first anniversary now behind him, Bischofberger has that mega-round in the bank.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

Francesco De Rubertis

Medicxi is rolling out its biggest fund ever to back Eu­rope's top 'sci­en­tists with strange ideas'

Francesco De Rubertis built Medicxi to be the kind of biotech venture player he would have liked to have known back when he was a full time scientist.

“When I was a scientist 20 years ago I would have loved Medicxi,’ the co-founder tells me. It’s the kind of place run by and for investigators, what the Medicxi partner calls “scientists with strange ideas — a platform for the drug hunter and scientific entrepreneur. That’s what I wanted when I was a scientist.”

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league Kim Smith

ViiV Healthcare has always been something unique in the global drug industry.

Owned by GlaxoSmithKline and Pfizer — with GSK in the lead as majority owner — it was created 10 years ago in a time of deep turmoil for the field as something independent of the pharma giants, but with access to lots of infrastructural support on demand. While R&D at the mother ship inside GSK was souring, a razor-focused ViiV provided a rare bright spot, challenging Gilead on a lucrative front in delivering new combinations that require fewer therapies with a more easily tolerated regimen.

They kept a massive number of people alive who would otherwise have been facing a death sentence. And they made money.

And throughout, John Pottage has been the chief scientific and chief medical officer.

Until now.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

Daniel O'Day

No­var­tis hands off 3 pre­clin­i­cal pro­grams to the an­tivi­ral R&D mas­ters at Gilead

Gilead CEO Daniel O’Day’s new task hunting up a CSO for the company isn’t stopping the industry’s dominant antiviral player from doing pipeline deals.

The big biotech today snapped up 3 preclinical antiviral programs from pharma giant Novartis, with drugs promising to treat human rhinovirus, influenza and herpes viruses. We don’t know what the upfront is, but the back end has $291 million in milestones baked in.

Vas Narasimhan, AP Images

On a hot streak, No­var­tis ex­ecs run the odds on their two most im­por­tant PhI­II read­outs. Which is 0.01% more like­ly to suc­ceed?

Novartis CEO Vas Narasimhan is living in the sweet spot right now.

The numbers are running a bit better than expected, the pipeline — which he assembled as development chief — is performing and the stock popped more than 4% on Thursday as the executive team ran through their assessment of Q2 performance.

Year-to-date the stock is up 28%, so the investors will be beaming. Anyone looking for chinks in their armor — and there are plenty giving it a shot — right now focus on payer acceptance of their $2.1 million gene therapy Zolgensma, where it’s early days. And CAR-T continues to underperform, but Novartis doesn’t appear to be suffering from it.

So what could go wrong?

Actually, not much. But Tim Anderson at Wolfe pressed Narasimhan and his development chief John Tsai to pick which of two looming Phase III readouts with blockbuster implication had the better odds of success.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

On a glob­al romp, Boehringer BD team picks up its third R&D al­liance for Ju­ly — this time fo­cused on IPF with $50M up­front

Boehringer Ingelheim’s BD team is on a global deal spree. The German pharma company just wrapped its third deal in 3 weeks, going back to Korea for its latest pipeline pact — this time focused on idiopathic pulmonary fibrosis.

They’re handing over $50 million to get their hands on BBT-877, an ATX inhibitor from Korea’s Bridge Biotherapeutics that was on display at a science conference in Dallas recently. There’s not a whole lot of data to evaluate the prospects here.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

Servi­er scoots out of an­oth­er col­lab­o­ra­tion with Macro­Gen­ics, writ­ing off their $40M

Servier is walking out on a partnership with MacroGenics $MGNX — for the second time.

After the market closed on Wednesday MacroGenics put out word that Servier is severing a deal — inked close to 7 years ago — to collaborate on the development of flotetuzumab and other Dual-Affinity Re-Targeting (DART) drugs in its pipeline.

MacroGenics CEO Scott Koenig shrugged off the departure of Servier, which paid $20 million to kick off the alliance and $20 million to option flotetuzumab — putting a heavily back-ended $1 billion-plus in additional biobuck money on the table for the anti-CD123/CD3 bispecific and its companion therapies.